A trial of pembrolizumab and radiotherapy for advanced melanoma (PERM)
Cancer type:
Status:
Phase:
This trial compared pembrolizumab with pembrolizumab and radiotherapy for melanoma skin cancer.
It was for people with melanoma skin cancer that could not be removed with surgery or had spread to other parts of the body.
Cancer Research UK supports this trial.
More about this trial
When this trial was done, pembrolizumab was one of the usual treatments for advanced melanoma. It is an 
. It works by helping the to recognise and attack cancer cells.
Radiotherapy is another treatment for advanced melanoma. It can help shrink the cancer or manage symptoms such as bone pain.
In this trial, researchers wanted to see if having pembrolizumab and radiotherapy could control the growth of the cancer for longer. Some people had pembrolizumab on its own and some had pembrolizumab and radiotherapy.
The main aims of the trial were to:
- find out if pembrolizumab and radiotherapy works better than pembrolizumab alone
- learn more about the side effects
Summary of results
This trial closed early as it was difficult to find enough people to take part. So the trial team won't be producing any results for this trial.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr James Larkin
Supported by
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Merck, Sharp & Dohme
NIHR Clinical Research Network: Cancer
Royal Marsden NHS Foundation Trust
Other information
This is Cancer Research UK trial number CRUK/14/036.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
